by Bioactive peptides are short chains of amino acids that have physiological effects in the human body beyond their nutritional value of protein breakdown products. They can modulate metabolic, physiological and cognitive functions and are increasingly being incorporated into food and beverages for their potential health benefits. Common bioactive peptides such as lactokinins, casokinins, cerebellins and glycosaminoglycans are used for controlling blood pressure, preventing osteoporosis and fighting obesity.
The global bioactive peptide market is estimated to be valued at US$ 11.29 Bn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Consumers are increasingly switching to functional foods and beverages with bioactive ingredients for their potential health benefits. This can help conditions like obesity, hypertension and osteoporosis. Bioactive peptides can offer these benefits without any negative side effects associated with synthetic drugs.
Another driver is the growing demand for plant-based and clean label products. Consumers want ingredients from recognizable sources with minimal processing and without artificial preservatives or flavors. Bioactive peptides derived from plants, mushrooms and fermentation meet these clean label requirements and are finding greater acceptance. This is supporting the growth of the overall bioactive peptide market.
SWOT Analysis
Strength: Bioactive peptide market has wide applications in food and beverages, cosmetics, and pharmaceutical industries. Bioactive peptides can enhance nutritional and health benefits. They have antihypertensive, immunomodulatory, antithrombotic, and antidiabetic properties. Incorporation of bioactive peptides in functional foods is gaining popularity.
Weakness: High production costs associated with obtaining bioactive peptides through isolation from natural sources or chemical and enzymatic synthesis methods. Regulatory compliance and safety norms add to the production costs.
Opportunity: Growing health-conscious consumer base is creating demand for naturally derived ingredients with therapeutic benefits. This provides opportunities for manufacturers to develop innovative products containing bioactive peptides. Rising spending capability on premium health foods also supports market growth.
Threats: Stringent regulations by food safety agencies to prevent adverse reactions can restrict product launches. Substitution threat from synthetic alternatives that are cheaper to produce also affects market revenue.
Key Takeaways
The Global Bioactive Peptide Market Size is expected to witness high growth. The market size for 2024 is US$ 11.29 Bn and is projected to reach US$ 20.60 Bn by 2031 at an impressive CAGR of 8%. North America currently dominates the market and is expected to maintain its lead due to increased health awareness and strong expenditure on premium health foods.
Regional analysis- North America is the largest market for bioactive peptides currently. The US contributes significantly to the regional market growth. Europe is the second largest regional market supported by rising spending on nutraceuticals. Asia Pacific is expected to emerge as the fastest growing regional market for bioactive peptides between 2024-2031 driven by expanding middle-class population and their willingness to spend on healthy products.
Key players operating in the bioactive peptide market are Archer Daniels Midland Company, Kerry Group, Cargill, Incorporated, DSM, Glanbia, DowDuPont, BASF, Fonterra Co-operative Group, Corbion, Arla Foods, and Ajinomoto Co. These players are focused on new product development and acquisition strategies to strengthen their market position.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
